Table 2.
Characteristics of Participants Stratified by Lipoprotein(a) Level in Propensity‐Matched Cohort
| Lipoprotein(a)≤50 mg/dL (n=1760) | Lipoprotein(a)>50 mg/dL (n=423) | P value | |
|---|---|---|---|
| Age, y | 66.04 (9.53) | 65.50 (9.78) | 0.30 |
| Female sex | 765 (43.5) | 221 (52.2) | 0.001 |
| Race or ethnicity | <0.001 | ||
| White | 957 (54.4) | 184 (43.5) | |
| Asian | 176 (10.0) | 19 (4.5) | |
| Black | 352 (20.0) | 181 (42.8) | |
| Hispanic | 275 (15.6) | 39 (9.2) | |
| BMI, kg/m2 | 28.39 (5.19) | 28.44 (5.33) | 0.85 |
| Hypertension | 997 (56.6) | 266 (62.9) | 0.02 |
| Diabetes | 290 (16.5) | 74 (17.5) | 0.67 |
| Current smoker | 164 (9.3) | 40 (9.5) | 0.95 |
| Statin use | 354 (20.1) | 125 (29.6) | <0.001 |
| Antihypertensive use | 856 (48.6) | 240 (56.7) | 0.003 |
| SBP, mm Hg | 129.91 (21.54) | 130.98 (23.06) | 0.37 |
| Total cholesterol, mg/dL | 186.51 (32.70) | 198.08 (37.68) | <0.001 |
| LDL‐C, mg/dL | 110.48 (29.55) | 122.44 (34.27) | <0.001 |
| HDL‐C, mg/dL | 49.92 (14.68) | 53.04 (15.15) | <0.001 |
| eGFR, mL/min per 1.73 m2 | 85.60 (20.38) | 84.98 (20.35) | 0.57 |
| CRP, mg/L | 3.67 (5.98) | 3.54 (5.20) | 0.70 |
| Oral anticoagulant use | 5 (0.3) | 1 (0.2) | >0.99 |
| NSAID use | 274 (15.6) | 55 (13.0) | 0.21 |
| History of blood clots | 55 (3.1) | 14 (3.3) | 0.96 |
| Liver disease | 70 (4.0) | 9 (2.1) | 0.09 |
| Family history ASCVD | 1080 (61.4) | 270 (63.8) | 0.38 |
| Aspirin use | 973 (55.3) | 261 (61.7) | 0.02 |
| CHD events | 156 (8.9) | 58 (13.7) | 0.004 |
| Follow‐up time, y | 16.5 [10.7–18.4] | 16.4 [9.1–17.2] | 0.04 |
Results are presented as mean (SD), median [interquartile range] or n (%). ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart disease; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; NSAID, nonsteroidal anti‐inflammatory drug; and SBP, systolic blood pressure.